author-photo

Lin Zhan

Pfizer

4

Papers

25

Citations

Citation Trend

Filter By

Papers (4) Sort By

JournalConferenceOthers

Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.

2021 Journal of Comparative Effectiveness Research
Show All
- Source
- Cite
- Save
Citations (1)
Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study

2021 Future Oncology
Show All
- Source
- Cite
- Save
Citations (0)
CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies.

2021 Future Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study

2019 Journal of Global Oncology
Show All
- Source
- Cite
- Save
Citations (20)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号